Related Experiment Videos
Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility
1Department of Surgical Oncology, Osaka Medical Center for Cancer and CVD, Higashinari, Japan. kmurata@yo.rim.or.jp
Abstract:
To investigate mechanisms for regulation of intracellular cAMP involved in cancer cell invasion, phosphodiesterase (PDE) activity in a colon cancer cell line, DLD-1, was studied. Activities of PDE 2, 4, and 5 were detected in DLD-1 cells by pharmacological approach. Specific and cell permeable inhibitors for those PDEs were used to determine which PDE is responsible for cAMP turnover involved in cancer cell motility. Treatment of DLD-1 cells with rolipram and Ro-20-1724 inhibitors for PDE 4, elevated intracellular cAMP contents three to five times of control. EHNA, an inhibitor for PDE 2, and zaprinast. an inhibitor for PDE 5, did not affect cAMP levels. To assess cellular motility, we utilized chemotaxis assay. EHNA and zaprinast did not suppress serum-induced chemotaxis. In contrast, rolipram and Ro-20-1724, suppressed chemotaxis in a dose dependent fashion. These suggest that PDE 4 plays a critical role in regulating intracellular cAMP levels of colon cancer cells and is involved in cancer invasion. PDE 4 can be a novel target of anti-invasion drug.
Insights
Phosphodiesterase 4 (PDE 4) regulates cyclic adenosine monophosphate (cAMP) in colon cancer cells, impacting their invasion. Inhibiting PDE 4 offers a potential strategy for anti-invasion drugs targeting cancer cell motility.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Intracellular cyclic adenosine monophosphate (cAMP) levels are crucial in regulating cancer cell invasion.
- Phosphodiesterases (PDEs) are key enzymes that hydrolyze cAMP, influencing cellular processes.
- Understanding PDE activity in colon cancer is vital for developing targeted therapies.
Purpose of the Study:
- To investigate the role of phosphodiesterase (PDE) activity in regulating intracellular cAMP levels within colon cancer cells.
- To determine which specific PDE isoenzymes (PDE 2, 4, and 5) are involved in colon cancer cell motility and invasion.
Main Methods:
- Pharmacological characterization of PDE 2, 4, and 5 activity in the DLD-1 colon cancer cell line.
- Utilizing specific PDE inhibitors (rolipram, Ro-20-1724 for PDE 4; EHNA for PDE 2; zaprinast for PDE 5) to assess cAMP levels.
- Employing chemotaxis assays to evaluate the impact of PDE inhibition on cancer cell motility.
Main Results:
- Inhibitors of PDE 4 (rolipram, Ro-20-1724) significantly increased intracellular cAMP levels (3-5 fold).
- Inhibitors of PDE 2 (EHNA) and PDE 5 (zaprinast) did not alter cAMP levels.
- PDE 4 inhibition suppressed serum-induced chemotaxis in a dose-dependent manner, while PDE 2 and 5 inhibition had no effect on motility.
Conclusions:
- Phosphodiesterase 4 (PDE 4) plays a critical role in controlling intracellular cAMP levels in colon cancer cells.
- PDE 4 activity is directly involved in regulating colon cancer cell invasion and motility.
- PDE 4 represents a promising novel therapeutic target for developing anti-invasion drugs in cancer treatment.